Tocilizumab in combination with corticosteroids: potential for managing cancer cachexia with systemic hyperinflammation
2024

Tocilizumab and Corticosteroids for Cancer Cachexia

Sample size: 40 publication 10 minutes Evidence: moderate

Author Information

Author(s): Chen Ping, Wang Dingyi, Zhan Zhouwei, Chen Ling, Chen Yu

Primary Institution: Fujian Cancer Hospital, Fuzhou, Fujian, China

Hypothesis

Tocilizumab would play a beneficial therapeutic role in cachexia associated with systemic hyperinflammation.

Conclusion

Tocilizumab, in combination with corticosteroids, is favorable for alleviating cancer cachexia with systemic hyperinflammation.

Supporting Evidence

  • Tocilizumab treatment improved symptom relief rates from 20% to 60%.
  • Patients treated with tocilizumab showed significant improvements in serum prealbumin and albumin levels.
  • 45% of patients in the tocilizumab group gained more than 2% of their body weight compared to 15% in the control group.
  • Tocilizumab did not increase infection rates compared to the control group.

Takeaway

This study looked at how a medicine called tocilizumab can help people with cancer who are losing weight and feeling very sick. It found that tocilizumab can help them feel better and gain some weight.

Methodology

This was a single-center retrospective controlled study comparing 20 patients treated with tocilizumab to a matched control group of 20 patients.

Potential Biases

Potential for selection bias due to the retrospective design.

Limitations

The study had a small sample size and was exploratory in nature.

Participant Demographics

20 males and 20 females with advanced cancer, primarily gastrointestinal cancer.

Statistical Information

P-Value

p = 0.024

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.3389/fimmu.2024.1477310

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication